Log In
BCIQ
Print this Print this
 

pasireotide (Signifor LAR)

Also known as: once-monthly Signifor

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionLong-acting release formulation of Signifor pasireotide, a somatostatin analog
Molecular Target Somatostatin receptor
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationAcromegaly
Indication DetailsTreat acromegaly
Regulatory Designation U.S. - Orphan Drug (Treat acromegaly);
U.S. - Undisclosed Review (Treat acromegaly);
EU - Standard Review (Treat acromegaly);
Australia - Orphan Drug (Treat acromegaly)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today